ISSN: 2577-2996

PROGRESS IN MEDICAL SCIENCES, 2024
VOL 8, NO. 4, PAGE 1 – 3
DOI: doi.org/10.47363/PMS/2024(8)215

REVIEW ARTICLE

Open Access

Advancements in Alzheimer's Disease Research: Targeting Beta-Amyloid Protein for Disease Management

Sama Abu Helou

School of Medicine, European University Cyprus, Europe

ABSTRACT

Objective: To provide a comprehensive overview of advancements in Alzheimer's treatment focusing on therapies targeting beta amyloid plaques and tau protein neurofibrillary tangles.

Methods: An analysis of recent studies and clinical trials, particularly on monoclonal antibodies like Aducanumab was conducted. Data were sourced from clinical trials including EMERGE and ENGAGE.

Results: Aducanumab has shown potential in reducing Aβ buildup and halting cognitive decline in early-stage AD. However, clinical trials yielded mixed results, indicating the need for further validation.

Conclusion: While Aducanumab's approval is a milestone, effective disease management remains challenging. Ongoing research is crucial to refine these therapies and explore new treatment avenues.

ARTICLE HISTORY

Received August 05, 2024
Accepted August 12, 2024
Published August 20, 2024

KEYWORDS

Alzheimer's Disease, Beta-Amyloid, Tau Protein, Aducanumab, Cognitive Decline, Neurodegeneration

Introduction

Alzheimer's disease (AD) is one of the most common and devastating neurodegenerative diseases, affecting about 55 million people worldwide. It accounts for 60%-80% of dementia cases. With an aging population, the prevalence of AD is expected to rise.

AD has a complex pathogenesis involving genetic, environmental, and lifestyle factors. In rare cases, a single gene variant causes AD, but most cases result from interactions among multiple genes and external factors. Changes in the brain, including beta-amyloid (Aβ) plaques and tau neurofibrillary tangles, are central to its development. These changes disrupt neuronal function, leading to widespread neurodegeneration.

Research shows that AD is linked to immune system changes, especially involving microglia cells in the brain. There may also be disturbances in synapses and energy production. Despite extensive research, the exact cause of AD remains unknown, though aging, environmental factors, and lifestyle contribute to its onset and progression.

Early stages of AD mainly affect the brain areas responsible for memory, leading to subtle cognitive impairments. As the disease progresses, significant neuronal loss and brain atrophy occur, resulting in severe cognitive decline.

Current treatments focus on symptom relief rather than slowing disease progression. Medications like cholinesterase inhibitors and NMDA antagonists temporarily improve memory and cognition but do not address the underlying pathology. The recent approval of Aducanumab, a monoclonal antibody targeting Aβ aggregates, has sparked interest. Aducanumab aims to reduce amyloid plaque burden and potentially alter disease progression, but its benefits and long-term efficacy are still under scrutiny.

This review explores the current understanding of AD pathophysiology, the mechanisms, and clinical implications of Aducanumab, and future research directions. By synthesizing recent findings, we aim to provide a comprehensive overview of AD and contribute to ongoing discussions on its management and treatment.

Aducanumab: Mechanism and Clinical Trials

Mechanism of Action

Aducanumab is a human monoclonal antibody that targets aggregated forms of beta-amyloid (Aβ), including soluble oligomers and insoluble fibrils. By binding selectively to these aggregates, aducanumab facilitates their clearance by microglial cells, the brain's primary immune cells. This mechanism is expected to reduce the formation of new plaques and mitigate the neurotoxic effects of existing plaques, potentially slowing the progression of Alzheimer's disease (AD). The pharmacokinetics of aducanumab indicate a long half-life, allowing for sustained therapeutic levels in the brain, which is critical for its efficacy

Preclinical Studies

In preclinical models, aducanumab demonstrated efficacy in reducing Aβ plaques in transgenic mice overexpressing human

Contact: Sama Abu Helou School of Medicine, European University Cyprus, Europe.

amyloid precursor protein. Acute treatment significantly reduced plaque burden, while chronic administration showed more modest effects. These findings provided the foundation for subsequent human trials, as they indicated that aducanumab could effectively target and reduce Aβ plaques in the brain.

Phase I Trials

The phase I trials primarily focused on assessing the safety, tolerability, and pharmacokinetics of aducanumab in healthy volunteers and patients with mild cognitive impairment (MCI) or mild AD. Results from these trials indicated that aducanumab was well-tolerated across a range of doses, with a linear pharmacokinetic profile. Participants receiving aducanumab showed a dose-dependent reduction in Aβ plaques, supporting further investigation in larger, longer-term trials

Phase II Trial

The phase Ib trial, known as PRIME, was designed to evaluate the effects of aducanumab on Aβ plaques and cognitive function in patients with MCI or mild AD. This randomized, double-blind, placebo-controlled study included multiple dose cohorts and extended over 54 weeks. Results showed a significant reduction in Aβ plaques, as visualized by positron emission tomography (PET) imaging and suggested potential cognitive benefits. These findings provided a strong rationale for advancing to phase III trials.

Phase III Trials: Emerge and Engage

The phase III trials, Emerge and Engage, were pivotal studies designed to confirm the efficacy and safety of aducanumab in a larger population of patients with early AD. These trials enrolled over 3,000 participants globally and were randomized, double-blind, and placebo controlled. Both trials aimed to assess the impact of high and low doses of aducanumab on cognitive and functional outcomes over 18 months.

Emerge

The EMERGE trial met its primary endpoint, showing a statistically significant reduction in clinical decline as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Patients receiving the high dose of aducanumab exhibited a reduction in Aβ plaques and an improvement in secondary endpoints related to cognition and daily functioning

Engage

The ENGAGE trial, however, did not meet its primary endpoint, showing no significant difference between the aducanumab and placebo groups. Post-hoc analyses suggested that inconsistencies in dosing and patient adherence might have influenced the results. Despite these mixed outcomes, a reanalysis of the data, considering high-dose patients from both trials, supported the FDA's decision to approve aducanumab.

Controversies and Challenges

The approval of aducanumab has been met with considerable debate and controversy.

Key Issues Include

Efficacy

While the EMERGE trial showed positive results, the failure of the ENGAGE trial to replicate these findings raised questions about the overall efficacy of aducanumab. Critics argue that the evidence of cognitive benefits is not robust enough to justify approval.

Side Effects

Aducanumab is associated with amyloid-related imaging abnormalities (ARIA), including brain edema (ARIA-E) and microhemorrhages (ARIA-H). These side effects are common but often asymptomatic. However, their potential severity necessitates careful patient monitoring and may limit the therapy's broader application.

Cost and Accessibility

Aducanumab's high cost, estimated at approximately $56,000 per year, poses significant challenges for healthcare systems and patients. The economic implications and issues of accessibility and equity are critical consideration.

Future Directions

The future of Alzheimer's disease (AD) research is poised to address several critical areas beyond the current focus on amyloid-beta (Aβ) and tau proteins.

Combination Therapies

Given the multifaceted nature of AD pathogenesis, combination therapies targeting multiple pathways simultaneously are gaining interest. These approaches may include combinations of Aβ and tau-targeting agents, anti-inflammatory drugs, neuroprotective agents, and lifestyle interventions. The goal is to achieve a synergistic effect that can more effectively slow or halt disease progression.

Biomarkers for Early Detection

Early and accurate diagnosis of AD remains a significant challenge. Advances in biomarker research, including cerebrospinal fluid (CSF) biomarkers, blood-based biomarkers, and neuroimaging techniques, are crucial for identifying individuals at risk before significant neurodegeneration occurs. The development of reliable, non-invasive biomarkers could enable earlier intervention, potentially improving outcomes.

Genetic and Epigenetic Research

Exploring the genetic and epigenetic factors that contribute to AD susceptibility and progression is another promising avenue. Understanding these factors can lead to personalized medicine approaches, where treatments are tailored to an individual's genetic makeup, potentially increasing the efficacy of therapeutic interventions.

Novel Therapeutic Targets

Beyond Aβ and tau, other targets are being investigated, such as neuro inflammation, mitochondrial dysfunction, synaptic health, and neurovascular integrity. Research into these areas may uncover new therapeutic strategies that could complement or provide alternatives to current treatments.

Technological Advancements

Emerging technologies, such as gene therapy, RNA-based therapies, and advanced drug delivery systems, hold promise for AD treatment. These technologies can potentially provide

more precise and effective delivery of therapeutics to the brain, overcoming some of the current limitations of AD treatments.

Precision Medicine

The application of precision medicine in AD involves tailoring treatments based on an individual's specific biological, genetic, and clinical characteristics. This approach aims to optimize therapeutic efficacy and minimize adverse effects by considering the unique aspects of each patient's disease profile.

Conclusion

The approval of aducanumab marks a pivotal moment in Alzheimer's disease treatment, representing the first FDA-approved therapy that targets the underlying pathology of the disease. Despite the controversies and challenges surrounding its efficacy and safety, aducanumab has opened the door for further advancements in disease-modifying treatments. The journey towards an effective cure for AD is ongoing, with promising avenues in combination therapies, early detection biomarkers, genetic research, and novel therapeutic targets. As research progresses, the hope is that these efforts will lead to more effective treatments, improved patient outcomes, and ultimately, a better quality of life for those affected by AD. The future of AD treatment holds significant promise, driven by continuous scientific innovation and a deeper understanding of the disease mechanisms [1-15].

References

[1] Alzheimer's Disease Fact Sheet. National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet.

[2] Draft Diagnostic Criteria for Alzheimer's Unveiled at AAIC. Alzheimer's Association. https://aaic.alz.org/releases_2023/new-alzheimers-diagnostic-criteria-unveiled.asp.

[3] Silvestro S, Valeri A, Mazzon E. Aducanumab and its effects on tau pathology: Is this the turning point of amyloid hypothesis? Int J Mol Sci. 2022; 23: 888.

[4] Bateman RJ, Xiong C, Benzinger TL, Fagan A M, Goate A, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. N Engl J Med. 2012; 367: 795-804.

[5] Sevigny J, Chiao P, Bussière T, Weinreb P H, Williams L, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016; 537: 50-56.

[6] Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2020; 16: 879-884.

[7] Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, et al. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. N Engl J Med. 2014; 370: 322-333.

[8] Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021; 384: 1691-1704.

[9] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297: 353-356.

[10] Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021; 7: e12179.

[11] Van Dyck CH. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. Biol Psychiatry. 2018; 83: 311-319.

[12] McDade E, Hauser D, Jiang H. Lecanemab in Patients with Early Alzheimer's Disease. N Engl J Med. 2022; 386:193-204.

[13] Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, et al. A randomized, double-blind, placebo-controlled phase 2 trial of tau antibody semorinemab in mild-to-moderate Alzheimer's disease. Alzheimers Res Ther 2021; 13: 80.

[14] Hampel H, O'Bryant SE, Castrillo JI, Ritchie C, Rojkova K, et al. Precision Medicine - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. J Prev Alzheimers Dis 2016; 3: 243-259.

[15] De Strooper B, Karran E. The Cellular Phase of Alzheimer's Disease. Cell. 2016; 164: 603-615.